Intestinal mucosal injury induced by tryptase-activated protease-activated receptor 2 requires β-arrestin-2 in vitro

Li,Shun; Guan,Jianqiang; Ge,Mian; Huang,Pinjie; Lin,Yiquan; Gan,Xiaoliang

doi:10.3892/mmr.2015.4325

Intestinal mucosal injury induced by tryptase-activated protease-activated receptor 2 requires β-arrestin-2 in vitro

Authors:
- Shun Li
- Jianqiang Guan
- Mian Ge
- Pinjie Huang
- Yiquan Lin
- Xiaoliang Gan
View Affiliations

Affiliations: Department of Anesthesiology, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Anesthesiology, Zhongshan Ophthalmic Center, Sun Yat‑sen University, Guangzhou, Guangdong 510060, P.R. China
Published online on: September 14, 2015 https://doi.org/10.3892/mmr.2015.4325
Pages: 7181-7187

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tryptase exacerbates intestinal ischemia-reperfusion injury, however, the direct role of tryptase in intestinal mucosal injury and the underlying mechanism remains largely unknown. Protease-activated receptor 2 (PAR‑2), commonly activated by tryptase, interacts with various adaptor proteins, including β‑arrestin‑2. The present study aimed to determine whether tryptase is capable of inducing intestinal mucosal cell injury via PAR‑2 activation and to define the role of β‑arrestin‑2 in the process of injury. The IEC‑6 rat intestinal epithelial cell line was challenged by tryptase stimulation. Cell viability, lactate dehydrogenase (LDH) activity and apoptosis were analyzed to determine the severity of cell injury. Injury was also evaluated following treatments with specific PAR‑2 and extracellular signal‑related kinases (ERK) inhibitors, and knockdown of β‑arrestin‑2. PAR‑2, ERK and β‑arrestin‑2 protein expression levels were evaluated. Tryptase treatment (100 and 1,000 ng/ml) resulted in IEC‑6 cell injury, as demonstrated by significant reductions in cell viability, accompanied by concomitant increases in LDH activity and levels of cleaved caspase‑3 protein expression. Furthermore, tryptase treatment led to a marked increase in PAR‑2 and phosphorylated‑ERK expression, and exposure to specific PAR‑2 and ERK inhibitors eliminated the changes induced by tryptase. Knockdown of β‑arrestin‑2 blocked tryptase‑mediated cell injury, whereas tryptase exerted no influence on β‑arrestin‑2 expression in IEC‑6 cells. These data indicate that tryptase may directly damage IEC‑6 cells via PAR-2 and the downstream activation of ERK, and demonstrate that the signaling pathway requires β-arrestin-2.

View Figures

View References

1	Brenner SA, Zacheja S, Schäffer M, Feilhauer K, Bischoff SC and Lorentz A: Soluble CD14 is essential for lipopolysaccharide-dependent activation of human intestinal mast cells from macroscopically normal as well as Crohn's disease tissue. Immunology. 143:174–183. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gan X, Liu D, Huang P, Gao W, Chen X and Hei Z: Mast-cell-releasing tryptase triggers acute lung injury induced by small intestinal ischemia-reperfusion by activating PAR-2 in rats. Inflammation. 35:1144–1153. 2012. View Article : Google Scholar
3	Gan X, Su G, Zhao W, Huang P, Luo G and Hei Z: The mechanism of sevoflurane preconditioning-induced protections against small intestinal ischemia reperfusion injury is independent of mast cell in rats. Mediators Inflamm. 2013:3787032013. View Article : Google Scholar : PubMed/NCBI
4	Hamilton MJ, Sinnamon MJ, Lyng GD, Glickman JN, Wang X, Xing W, Krilis SA, Blumberg RS, Adachi R, Lee DM and Stevens RL: Essential role for mast cell tryptase in acute experimental colitis. Proc of the Natl Acad Sci USA. 108:290–295. 2011. View Article : Google Scholar
5	Zhao W, Zhou S, Yao W, Gan X, Su G, Yuan D and Hei Z: Propofol prevents lung injury after intestinal ischemia-reperfusion by inhibiting the interaction between mast cell activation and oxidative stress. Life Sci. 108:80–87. 2014. View Article : Google Scholar : PubMed/NCBI
6	Zhao P, Metcalf M and Bunnett NW: Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne). 5:672014.
7	Rothmeier AS and Ruf W: Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 34:133–149. 2012. View Article : Google Scholar
8	Yoshida N, Takagi T, Isozaki Y, Suzuki T, Ichikawa H and Yoshikawa T: Proinflammatory role of protease-activated receptor-2 in intestinal ischemia/reperfusion injury in rats. Mol Med Rep. 4:81–86. 2011.PubMed/NCBI
9	Kang DS, Tian X and Benovic JL: Role of β-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr Opin Cell Biol. 27:63–71. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zoudilova M, Min J, Richards HL, Carter D, Huang T and DeFea KA: beta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. J Biol Chem. 285:14318–14329. 2010. View Article : Google Scholar : PubMed/NCBI
11	Jacob C, Yang PC, Darmoul D, Amadesi S, Saito T, Cottrell GS, Coelho AM, Singh P, Grady EF, Perdue M and Bunnett NW: Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem. 280:31936–31948. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ge L, Shenoy SK, Lefkowitz RJ and DeFea K: Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem. 279:55419–55424. 2004. View Article : Google Scholar : PubMed/NCBI
13	Fan H, Bitto A, Zingarelli B, Luttrell LM, Borg K, Halushka PV and Cook JA: Beta-arrestin 2 negatively regulates sepsis-induced inflammation. Immunology. 130:344–351. 2010. View Article : Google Scholar : PubMed/NCBI
14	Ho J, Du Y, Wong OG, Siu MK, Chan KK and Cheung AN: Downregulation of the gli transcription factors regulator kif7 facilitates cell survival and migration of choriocarcinoma cells. PLoS One. 9:e1082482014. View Article : Google Scholar : PubMed/NCBI
15	Du RW, Du RH and Bu WG: β-Arrestin 2 mediates the anti-inflammatory effects of fluoxetine in lipopolysaccharide-stimulated microglial cells. J Neuroimmune Pharmacol. 9:582–590. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC, Benovic JL and Daaka Y: Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA. 106:9379–9384. 2009. View Article : Google Scholar : PubMed/NCBI
17	Liu D, Gan X, Huang P, Chen X, Ge M and Hei Z: Inhibiting tryptase after ischemia limits small intestinal ischemia-reperfusion injury through protease-activated receptor 2 in rats. J Trauma Acute Care Surg. 73:1138–1144. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wang ZY, Wang P and Bjorling DE: Role of mast cells and protease-activated receptor-2 in cyclooxygenase-2 expression in urothelial cells. Am J Physiol Regul Integr Comp Physiol. 297:R1127–R1135. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pejler G, Rönnberg E, Waern I and Wernersson S: Mast cell proteases: Multifaceted regulators of inflammatory disease. Blood. 115:4981–4990. 2010. View Article : Google Scholar : PubMed/NCBI
20	Cui Y, Dahlin JS, Feinstein R, Bankova LG, Xing W, Shin K, Gurish MF and Hallgren J: Mouse mast cell protease-6 and MHC are involved in the development of experimental asthma. J Immunol. 193:4783–4789. 2014. View Article : Google Scholar : PubMed/NCBI
21	Eliakim R, Karmeli F, Okon E and Rachmilewitz D: Ketotifen effectively prevents mucosal damage in experimental colitis. Gut. 33:1498–1503. 1992. View Article : Google Scholar : PubMed/NCBI
22	Hagel AF, deRossi T, Zopf Y, Konturek P, Dauth W, Kressel J, Hahn EG and Raithel M: Mast cell tryptase levels in gut mucosa in patients with gastrointestinal symptoms caused by food allergy. Int Arch Allergy Immunol. 160:350–355. 2013. View Article : Google Scholar
23	Tsujii K, Andoh T, Ui H, Lee JB and Kuraishi Y: Involvement of tryptase and proteinase-activated receptor-2 in spontaneous itch-associated response in mice with atopy-like dermatitis. J Pharmacol Sci. 109:388–395. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ebeling C, Forsythe P, Ng J, Gordon JR, Hollenberg M and Vliagoftis H: Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. J Allergy Clin Immunol. 115:623–630. 2005. View Article : Google Scholar : PubMed/NCBI
25	Groschwitz KR, Wu D, Osterfeld H, Ahrens R and Hogan SP: Chymase-mediated intestinal epithelial permeability is regulated by a protease-activating receptor/matrix metalloproteinase-2-dependent mechanism. Am J Physiol Gastrointest Liver Physiol. 304:G479–G489. 2013. View Article : Google Scholar : PubMed/NCBI
26	Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM and DeFea KA: Beta-arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem. 282:20634–20646. 2007. View Article : Google Scholar : PubMed/NCBI
27	Nichols HL, Saffeddine M, Theriot BS, Hedge A, Polley D, El-Mays T, Vliagoftis H, Hollenberg MD, Wilson EH, Walker JK and DeFea KA: β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proc Natl Acad Sci USA. 109:16660–16665. 2012. View Article : Google Scholar
28	Darling NJ and Cook SJ: The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. Biochim Biophys Acta. 1843:2150–2163. 2014. View Article : Google Scholar : PubMed/NCBI